SZodixStudyAcademic Library
ShelvesOpen access
Study · an open academic library·Metadata from OpenAlex (CC0)·Shelves·OpenAlex metadata, de-duplicated
Future Drug Prices and Cost-Effectiveness Analyses
6 references·1 citing·24 second hop
Future Drug Prices and Cost-Effectiveness Analyses (2008)Future Drug Prices and Cost-Effectiveness…Decision Modelling For Health Economic Evaluation (2006)Decision Modelling For Health…Methods for the Economic Evaluation of Health Care Programmes (2005)Methods for the Economic Eval…The green book : appraisal and evaluation in central government (2003)The green book : appraisal an…Principles of Good Practice for Decision Analytic Modeling in Health-Care Evaluation: Report of the ISPOR Task Force on Good Research Practices—Modeling Studies (2003)Principles of Good Practice f…Modelling the cost effectiveness of interferon beta and glatiramer acetate in the management of multiple sclerosisCommentary: Evaluating disease modifying treatments in multiple sclerosis (2003)Modelling the cost effectiven…Cost-Effectiveness in Health and Medicine (1996)Cost-Effectiveness in Health …Accounting for the Drug Life Cycle and Future Drug Prices in Cost-Effectiveness Analysis (2010)Accounting for the Drug Life …Probabilistic Sensitivity Analysis Using Monte Carlo Simulation (1985)Time Preference (1996)Limitations of Acceptability Curves for Presenting Uncertainty in Cost-Effectiveness Analysis (2007)Access with Evidence Development Schemes (2010)Cost-effectiveness of disease-modifying therapy for multiple sclerosis (2011)Brand Loyalty, Entry, and Price Competition in Pharmaceuticals after the 1984 Drug Act (1992)The NICE Cost-Effectiveness Threshold (2008)Good Research Practices for Measuring Drug Costs in Cost-Effectiveness Analyses: A Societal Perspective: The ISPOR Drug Cost Task Force Report—Part II (2009)Cost-Benefit Analysis: Concepts and Practice (1996)The Proper Scope of Government: Theory and an Application to Prisons (1997)The world economy: a millennial perspective (2001)Using Discrete Choice Experiments to Value Health and Health Care (2007)What you Should Know about Megaprojects and Why: An Overview (2014)Stern Review on the Economics of Climate Change (2006) (2017)EQ-SD: a measure of health status from the EuroQol Group (2001)Innovation in the pharmaceutical industry: New estimates of R&D costs (2016)Recommendations for Conduct, Methodological Practices, and Reporting of Cost-effectiveness Analyses (2016)The estimation of a preference-based measure of health from the SF-36 (2002)Systematic reviews: CRD's guidance for undertaking reviews in health care (2010)Principles of Good Practice for Budget Impact Analysis: Report of the ISPOR Task Force on Good Research Practices—Budget Impact Analysis (2007)Model Transparency and Validation (2012)Modeling Good Research Practices—Overview: A Report of the ISPOR-SMDM Modeling Good Research Practices Task Force-1 (2012)Evidence Synthesis for Decision Making 2 (2012)Model Parameter Estimation and Uncertainty Analysis (2012)
this work references cited by second hop

References

  • 2005Methods for the Economic Evaluation of Health Care Programmes13,647 cited
  • 1996Cost-Effectiveness in Health and Medicine7,192 cited
  • 2006Decision Modelling For Health Economic Evaluation3,144 cited
  • 2003The green book : appraisal and evaluation in central government1,417 cited
  • 2003Principles of Good Practice for Decision Analytic Modeling in Health-Care Evaluation: Report of the ISPOR Task Force on Good Research Practices—Modeling Studies1,170 cited
  • 2003Modelling the cost effectiveness of interferon beta and glatiramer acetate in the management of multiple sclerosisCommentary: Evaluating disease modifying treatments in multiple sclerosis142 cited

Cited by

  • 2010Accounting for the Drug Life Cycle and Future Drug Prices in Cost-Effectiveness Analysis53 cited

Only edges whose both ends are imported exist here. Widen the year window, or show the whole map. Back to the work